Gilead supports the efforts of governments and partners with professional organizations, patient advocacy groups, payers and healthcare professionals who have declared their intention and commitment to work toward the WHO goal of eliminating viral hepatitis around the world by 2030. Some of the defining features of the WHO goal are:
- 90% reduction in new HCV cases (e.g., screening of blood donations and risk reduction)
- 90% diagnosis of those infected with HCV
- 80% of eligible people with HCV treated
- 65% reduction in death
Micro-‐elimination focuses on breaking down national and international elimination goals into smaller goals which are relevant for defined populations.
Micro-‐elimination efforts require stakeholders to set pragmatic goals, while the people who are best informed about the HCV epidemic in a sub-‐population can tailor research to address local circumstances where data is needed.
In an effort to support micro-elimination efforts, the Gilead Medical Affairs team will support individual projects of no more than $350,000 USD or equivalent sum. It is Gilead’s intent to support up to 30 well-‐defined projects.
Successful projects should demonstrate clear objectives, defined timelines, a comprehensive operational plan, and proposed data which has relevance to the medical community and policy makers. Investigators should consider a presentation of findings to policy makers, with an aim of providing relevant evidence to support governmental or organizational public health objectives with respect to HCV elimination, where applicable, consistent with WHO goals.
Gilead will not consider requests solely for HCV screening costs (including test kits) or proposals which include HCV study drug. Proposals should be agnostic to a specific HCV drug.
Gilead will consider support for research proposals that do the following:
- Focus on a defined population such as but not limited to:
- Specific demographic
- Defined geographical area such as neighborhood, city, state, or region
- Discrete population within a health care network or system
- Focus on a data gap for the defined population. Examples include:
- Surveillance data pertaining to the cascade of care in geographies or populations which currently have inadequate data or strategic information systems for monitoring HCV infection
- Preventative strategies pertaining to: unsafe blood transfusion, health care injections, or harm reduction strategies
Understanding or intervening on a ‘leakage in the cascade’
- Consider presenting data to policy makers
Letter of intent should adhere to the following:
- Sponsoring institution has not already received a grant from a Gilead Medical Affairs Program (i.e., CITE, SCALE, or NoCo) or is currently receiving support from FOCUS
- Proposed budget is ≤ $350,000 USD equivalents
- Including overhead costs and applicable taxes
- Proposed overhead costs are ≤ 30% of the total budget
- The proposed study design will not take longer than 24 months to complete
- Funding for sole purpose of screening costs is not acceptable for CHIME
- Funding for or contribution of HCV study drug is not acceptable for CHIME
- No more than one subsite that will require contract negotiations and/or Institutional Review Board (IRB) or Ethics Committee (EC) review, or other barriers that will lead to delays in study start-up
Key Dates & Program Specifics:
• Gilead will evaluate and award submissions on a rolling basis during monthly reviews.
• Letter of Intent (LOI) – should be entered into the provided template. Proposals should not exceed 1,000 word limit
– 30 April 2018: LOI submission window opens
– 30 Sept 2018: LOI submission window closes
LOI applicants should use the downloadable LOI Form available at
LOI forms and Overhead Policy forms should be submitted to: Chime@gilead.com.
Full application submissions should be made by clicking on Apply Online at http://www.gilead.com/research/investigator-‐sponsored
Apply by September 30 2018